Shaare Zedek Medical Center

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

• Shaare Zedek Medical Center

  Jerusalem, Jerusalem 9103102

  187 trials

• Shaare Zedek Medical Center (Site 0075)

  Jerusalem, 9103102

  7 trials

• Shaare Zedek Medical Center (Site 1710)

  Jerusalem, 9103102

  3 trials

  • NCT06008756Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

  • NCT05952856A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

  • NCT05952869A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

• Shaare Zedek Medical Center, Jerusalem 91031

  Jerusalem, 9103102

  2 trials

  • NCT04771273A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  • NCT04509674EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

• Shaare-Zedek Medical Center, Oncology Institute

  Jerusalem, 9103102

  2 trials

  • NCT06452277A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • NCT04958239A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

• Shaare Zedek Medical Center (Site 1404)

  Jerusalem, 9103102

  2 trials

  • NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

  • NCT05144841A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

• Shaare Zedek Medical Center (Site 1405)

  Jerusalem, 9103102

  2 trials

  • NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

    Contact: Study Coordinator

  • NCT05116189Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

• Shaare Zedek Medical Center (Site 1706)

  Jerusalem, 9103102

  2 trials

  • NCT07190248A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

    Contact: Study Coordinator

  • NCT06393374Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    Contact: Study Coordinator

• Shaare Zedek Medical Centre

  Jerusalem

  2 trials

  • NCT04936620Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling

    Contact: Cezar Mizrahi (principal investigator)

  • NCT03573089Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

    Contact: Linda Shavit

• 3760023 - Shaare Zedek Medical Center

  Jerusalem, 91031

  1 trial

  • NCT03473223Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

• Digestive Disease Institute, Shaare Zedek Medical Center

  Jerusalem, 9103102

  1 trial

  • NCT06233461A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

    Contact: Ariella Shitrit (principal investigator)

• Shaare Zedek Medical Center, 12 Shmuel Biet Street

  Jerusalem, 91031

  1 trial

  • NCT04127578Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

• Shaare Zedek Medical Center, Digestive Diseases Institute

  Jerusalem, 91004

  1 trial

  • NCT05611671A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

• Shaare Zedek Medical Center /ID# 126638

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

• Shaare Zedek Medical Center /ID# 130275

  Jerusalem, 91031

  1 trial

  • NCT02163694A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

• Shaare Zedek Medical Center /ID# 144277

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT02130362A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)

• Shaare Zedek Medical Center /ID# 163139

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT03006068A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

• Shaare Zedek Medical Center /ID# 163541

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT03105102A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

• Shaare Zedek Medical Center /ID# 163543

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT03398135A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

• Shaare Zedek Medical Center /ID# 171068

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT03105102A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

• Shaare Zedek Medical Center /ID# 207896

  Jerusalem, 91031

  1 trial

  • NCT03659669A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice

• Shaare Zedek Medical Center /ID# 223549

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT04524611Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

• Shaare Zedek Medical Center /ID# 228016

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT03987958A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)

• Shaare Zedek Medical Center /ID# 233092

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT04026113Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

• Shaare Zedek Medical Center /ID# 233181

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT04401748Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

• Shaare Zedek Medical Center /ID# 239485

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT05028569Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

• Shaare Zedek Medical Center /ID# 239699

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT04102020A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

• Shaare Zedek Medical Center /ID# 245681

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT06158841Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

• Shaare Zedek Medical Center /ID# 247259

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT05748483Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine

• Shaare Zedek Medical Center /ID# 247319

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT04780516Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care

• Shaare Zedek Medical Center /ID# 247833

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT05081557A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

• Shaare Zedek Medical Center /ID# 254169

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT05827887An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants

• Shaare Zedek Medical Center /ID# 254832

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT05782907Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

• Shaare Zedek Medical Center /ID# 254951

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT05995353A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

• Shaare Zedek Medical Center /ID# 256253

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT06063967A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

• Shaare Zedek Medical Center /ID# 257715

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT06107426Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

• Shaare Zedek Medical Center /ID# 258529

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT06257875A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

• Shaare Zedek Medical Center /ID# 258738

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT05841537An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

• Shaare Zedek Medical Center /ID# 259253

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT06107413Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

• Shaare Zedek Medical Center /ID# 259796

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT05578976A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

• Shaare Zedek Medical Center /ID# 262432

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT06236438Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

• Shaare Zedek Medical Center /ID# 262738

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT06346288A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

• Shaare Zedek Medical Center /ID# 267752

  Jerusalem, 9103102

  1 trial

  • NCT06628310A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

• Shaare Zedek Medical Center /ID# 268009

  Jerusalem, 9103102

  1 trial

  • NCT06820463A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

• Shaare Zedek Medical Center /ID# 269459

  Jerusalem, 9103102

  1 trial

  • NCT05445778Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

• Shaare Zedek Medical Center /ID# 270095

  Jerusalem, 9103102

  1 trial

  • NCT06568939A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

• Shaare Zedek Medical Center /ID# 275854

  Jerusalem, 9103102

  1 trial

  • NCT07024784A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

• Shaare Zedek Medical Center /ID# 276209

  Jerusalem, Jerusalem 91031

  1 trial

  • NCT07227896Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

    Contact: Lars Bergmann

• Shaare Zedek Medical Center /ID# 276244

  Jerusalem, 9103102

  1 trial

  • NCT05005403Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

• Shaare Zedek Medical Center /ID# 278712

  Jerusalem, 9103102

  1 trial

  • NCT07581002A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

• Shaare Zedek Medical Center Jerusalem

  Jerusalem, 9312584

  1 trial

  • NCT06398743First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer

• Shaare Zedek Medical Center - Jerusalem, ISRAEL

  Jerusalem, 91031

  1 trial

  • NCT05528510A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

• Shaare Zedek Medical Center, Neurology Clinics,

  Jerusalem, 9103102

  1 trial

  • NCT05843721Post-marketing Clinical Follow-up for Long-term Use of Intranasal Kinetic Oscillation in Subjects With Chronic Migraine

• Shaare Zedek Medical Center - Pulmonary Institute

  Jerusalem, 9103102

  1 trial

  • NCT06052267A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

• Shaare Zedek Medical Center (Site 0186)

  Jerusalem, 9103102

  1 trial

  • NCT07286149A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 0201)

  Jerusalem, 9103102

  1 trial

  • NCT06843447A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 0303)

  Jerusalem, 9103102

  1 trial

  • NCT05853367Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

• Shaare Zedek Medical Center (Site 0331)

  Jerusalem, 9103102

  1 trial

  • NCT04732221A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

• Shaare Zedek Medical Center (Site 0366)

  Jerusalem, 9103102

  1 trial

  • NCT07419295A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 0468)

  Jerusalem, 9103102

  1 trial

  • NCT06925737A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 0559)

  Jerusalem, 9103102

  1 trial

  • NCT03898180Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

• Shaare Zedek Medical Center (Site 0601)

  Jerusalem, 9103102

  1 trial

  • NCT05446870Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

• Shaare Zedek Medical Center (Site 0603)

  Jerusalem, 9103102

  1 trial

  • NCT07519772A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 0679)

  Jerusalem, 9103102

  1 trial

  • NCT06136650A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 0801)

  Jerusalem, 9103102

  1 trial

  • NCT07709000A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 0805)

  Jerusalem, 9103102

  1 trial

  • NCT06465186A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

• Shaare Zedek Medical Center (Site 0809)

  Jerusalem, 9103102

  1 trial

  • NCT03924856Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

• Shaare Zedek Medical Center (Site 0842)

  Jerusalem, 9103102

  1 trial

  • NCT03924895Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

• Shaare Zedek Medical Center (Site 1003)

  Jerusalem, 9103102

  1 trial

  • NCT05298423Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

• Shaare Zedek Medical Center (Site 1005)

  Jerusalem, 9103102

  1 trial

  • NCT03740165Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

• Shaare Zedek Medical Center (Site 1108)

  Jerusalem, 9103102

  1 trial

  • NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

• Shaare Zedek Medical Center (Site 1208)

  Jerusalem, 9103102

  1 trial

  • NCT06430801A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 1300)

  Jerusalem, 9103102

  1 trial

  • NCT06422143Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 1366)

  Jerusalem, 9103102

  1 trial

  • NCT03635567Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

• Shaare Zedek Medical Center (Site 1406)

  Jerusalem, 9103102

  1 trial

  • NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 1601)

  Jerusalem, 9103102

  1 trial

  • NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 1700)

  Jerusalem, 9103102

  1 trial

  • NCT06074588Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

• Shaare Zedek Medical Center (Site 1715)

  Jerusalem, 91031

  1 trial

  • NCT04945460A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

• Shaare Zedek Medical Center (Site 1735)

  Jerusalem, 9103102

  1 trial

  • NCT06492291Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

• Shaare Zedek Medical Center (Site 1905)

  Jerusalem, 9103102

  1 trial

  • NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 2020)

  Jerusalem, 9103102

  1 trial

  • NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 2206)

  Jerusalem, 9103102

  1 trial

  • NCT06312137A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 2503)

  Jerusalem, 9103102

  1 trial

  • NCT06132958Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

• Shaare Zedek Medical Center (Site 2602)

  Jerusalem, 9103102

  1 trial

  • NCT04924101Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

• Shaare Zedek Medical Center (Site 3200)

  Jerusalem, 9103102

  1 trial

  • NCT06780137A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 3301)

  Jerusalem, 9103102

  1 trial

  • NCT07513376A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    Contact: Study Coordinator

• Shaare Zedek Medical Center (Site 3704)

  Jerusalem, 9103102

  1 trial

  • NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    Contact: Study Coordinator

• Shaare Zedek Medical Center,Substudy-01

  Jerusalem, 9103102

  1 trial

  • NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer

• Shaare Zedek Medical Center,Substudy-02

  Jerusalem, 9103102

  1 trial

  • NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer

• Shaare Zedek Medical Center,Substudy-03

  Jerusalem, 9103102

  1 trial

  • NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer

• Shaare Zedek Medical Center (SZMC) - Site #492

  Jerusalem, 91031

  1 trial

  • NCT05248646Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

• Shaare Zedek Medical Center - The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition

  Jerusalem

  1 trial

  • NCT06777706Open Label Study to Assess Safety & Efficacy of QD for Induction of Remission in Pediatric Patients with UC

• Shaare Zedek Medical Center (SZMC)

  Jerusalem, 91031